BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $532 | +3.9% | 73,765 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $512 | -13.8% | 73,765 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $594 | -26.8% | 73,765 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $811 | -99.9% | 73,765 | 0.0% | 0.00% | -33.3% |
| Q3 2022 | $895,000 | +14.6% | 73,765 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $781,000 | -35.6% | 73,765 | 0.0% | 0.00% | -33.3% |
| Q1 2022 | $1,213,000 | +35.7% | 73,765 | +10.0% | 0.00% | +50.0% |
| Q4 2021 | $894,000 | -3.2% | 67,065 | +2.8% | 0.00% | -33.3% |
| Q3 2021 | $924,000 | -7.1% | 65,265 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $995,000 | +54.7% | 65,265 | 0.0% | 0.00% | +50.0% |
| Q1 2021 | $643,000 | -12.4% | 65,265 | -38.0% | 0.00% | -33.3% |
| Q4 2020 | $734,000 | +3.2% | 105,265 | -41.6% | 0.00% | 0.0% |
| Q3 2020 | $711,000 | +611.0% | 180,265 | +472.3% | 0.00% | +200.0% |
| Q3 2019 | $100,000 | -56.3% | 31,500 | -50.0% | 0.00% | 0.0% |
| Q2 2019 | $229,000 | -17.0% | 63,000 | +63.6% | 0.00% | -50.0% |
| Q1 2019 | $276,000 | +10.0% | 38,500 | +22.2% | 0.00% | 0.0% |
| Q4 2018 | $251,000 | -9.1% | 31,500 | -18.2% | 0.00% | 0.0% |
| Q3 2018 | $276,000 | +20.5% | 38,500 | -2.5% | 0.00% | +100.0% |
| Q2 2018 | $229,000 | +21.2% | 39,500 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $189,000 | +96.9% | 39,500 | +12.9% | 0.00% | 0.0% |
| Q1 2016 | $96,000 | -75.3% | 35,000 | -5.4% | 0.00% | -75.0% |
| Q4 2015 | $388,000 | -6.7% | 37,000 | +1.4% | 0.00% | -20.0% |
| Q3 2015 | $416,000 | -20.5% | 36,500 | +4.3% | 0.01% | -16.7% |
| Q2 2015 | $523,000 | +72.0% | 35,000 | +3.9% | 0.01% | +50.0% |
| Q1 2015 | $304,000 | -34.9% | 33,700 | -12.7% | 0.00% | -33.3% |
| Q4 2014 | $467,000 | +13.3% | 38,600 | -8.3% | 0.01% | 0.0% |
| Q3 2014 | $412,000 | -19.2% | 42,100 | +5.2% | 0.01% | -25.0% |
| Q2 2014 | $510,000 | +32.1% | 40,000 | +9.6% | 0.01% | +33.3% |
| Q1 2014 | $386,000 | – | 36,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |